fda approves first oral glp-1 obesity drug august 14 2025 A new option is now part of medicine. approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, for adults with obesity or overweight with at least one weight-related FDA Approves Lilly's Oral GLP-1

Glutathione acts as a shield, helping to prevent oxidative stress and long-term skin damage

Virtual care made it easier with my busy schedule. Robert, 50 Diabetes and Weight Management Ozempic helped lower my A1C from 8.1% to 5.9% and I lost 25 lbs in six months

Does it really work the way people claim

6 bottles of Bacteriostatic Water 30mL

Sexual dysfunction and sex hormone abnormalities in patients with cirrhosis: review of pathogenesis and management

In addition to GLP-1RAs, pioglitazone and SGLT-2 inhibitors are two other classes of diabetic medications that have shown promise in reducing the risk of cardiovascular disease, albeit through different mechanisms